Vero Beach, April 25th, 2016 – Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the FDA for its Pritumumab product for the treatment of Pancreatic cancer. According to Industry statistics, there are approximately 49,000 new cases of Pancreatic Cancer in the United States, annually, with a five year survival rate of 7% and few viable treatment options. This is the second Orphan Drug Designation Granted to Nascent Biotech from the FDA, the first being for use in Primary Brain Cancer.
Dr. Mark Glassy, Nascent Biotech’s founder and Advisory Board Chairman stated, “”It is very satisfying that the FDA has acknowledged the power and importance of Pritumumab in its broad effectiveness in cancer, especially in the un-met need of pancreatic cancer.” He further stated that “We hope to continue to identify additional Orphan Drug Cancers for which Pritumumab will have a significant therapeutic benefit.”
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Information:
Nascent Biotech, Inc.
Sean Carrick
President | CEO
601 21st Street Suite 300
Vero Beach, FL 32960
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com
